Table 1.
Clinical Parameters in AAT-Treated Subjectsa
| Baseline | Time After Initiation of AAT Therapy |
|||||
|---|---|---|---|---|---|---|
| 3 mo | 6 mo | 12 mo | 18 mo | 24 mo | ||
| HbA1c, % | 6.0 ± 0.51 (10) | 6.2 ± 0.65 (9) | 6.5 ± 0.61 (11) | 7.0 ± 1.7 (9) | 6.6 ± 0.74 (8) | 6.65 ± 0.64 (6) |
| Blood glucose, mg/dL | 119.5 ± 21.4 (10) | 124.9 ± 33.1 (9) | 137.0 ± 34.2 (10) | 148.7 ± 60.3 (10) | 152.1 ± 46.4 (9) | 129.8 ± 55.5 (5) |
| Insulin use, U/d | 20.2 ± 13.8 (10) | 22.5 ± 9.9 (9) | 26.0 ± 12.8 (10) | 35.1 ± 15.1 (10) | 32.4 ± 15.6 (9) | 30.7 ± 9.2 (5) |
| C-peptide AUC, ng/mL | 269.9 ± 127.7 (10) | 264.5 ± 138.8 (11) | 213.6 ± 84.9 (12) | 178.3 ± 151.0 (12) | 162.43 ± 101.7 (9) | 137.1 ± 70.8 (7) |
a
Data are means ± SD. Values in parentheses represent subject number.